Cowen Remains Bullish on Spark Therapeutics (ONCE) Following Top-Line SPK-RPE65 Results

Roth Capital Raises Price Target on Spark Therapeutics (ONCE) to $90 Following Top-Line Results

Roth Capital reiterated a Buy rating on Spark Therapeutics (NASDAQ: ONCE), and raised the price target to $90.00 (from $71.00), following the announced top-line results for the Phase 3 trial of SPKRPE65. The reported study represents the first successful controlled gene therapy trial. Spark... More

Pre-Open Stock Movers 10/05: (ONCE) (FOLD) (TWTR) Higher; (APP) (FEYE) (VRX) Lower (more...)

Spark Therapeutics (NASDAQ: ONCE) 37.4% HIGHER; announced positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product candidate, SPK-RPE65, for the treatment of RPE65-mediated inherited retinal dystrophies (IRDs). The pivotal trial met its primary endpoint (p = 0.001), demonstrating improvement of functional vision in the intervention group compared to the control group, as measured by the change in bilateral mobility testing between baseline and one year.

American Apparel, Inc. (NYSE: APP) 24% LOWER; files Chapter 11

AmicusTherapeutics... More

Spark Therapeutics (ONCE) Announces SPK-RPE65 Phase 3 Met Primary Endpoint

Spark Therapeutics (NASDAQ: ONCE) announced positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product candidate, SPK-RPE65, for the treatment of RPE65-mediated inherited retinal dystrophies (IRDs).

The pivotal trial met its primary endpoint (p = 0.001), demonstrating improvement of functional vision in the intervention group compared to the control group, as measured by the change in bilateral mobility testing between baseline and one year.

There were no serious adverse events related to SPK-RPE65 or deleterious immune responses observed in the trial.... More